Heart Failure

Scott Solomon, MD, and Alvin Chandra, MD, discuss the findings of the PARADIGM-HF and QoL trial, and sacubitril's effect on HF patients quality of life.

Lisa Rathman, MSN, of Lancaster General Hospital, discusses the benefits of subcutaneous furosemide in nursing homes and facilities outside the hospital.

Gregg Fonarow, MD; David Aguilar, MD; Rob Mentz, MD; and James Januzzi, MD, discuss the unexpected and exciting use of SGLT-2 inhibitors to treat heart failure.

Rob Mentz, MD, of Duke University Medical School, discusses the CANVAS trial and the pursuit of using SGLT-2 inhibitors to treat heart failure.

Despite the results of a large-scale trial, some experts questioned the use of beta-blockers for patients that suffered from heart failure and simultaneous AFib when in the presence of beta-adverse medications, like amiodarone.

The drug reduced cardiovascular risk in people with prior heart attack and inflammatory atherosclerosis.

Using the database from the 40-country, double-blind phase 3 ARISTOTLE study, which has been around for over 5 years, a sub-analysis was conducted by Renato Lopes, MD, PhD, professor of Medicine at Duke University in Durham, North Carolina and colleagues.

The Absorb GT1 Bioresorbable Vascular Stent raised concerns at the FDA.

Drugs were as effective in CTO patients as PCI, Korean study found.

Endotracheal intubation may do more harm than good.

In just over a year, Praluent has shown benefits in helping patients lower their cholesterol level. Despite the progress, there have also been some challenges.

The mysterious sudden deaths of apparently healthy people, some young and engaged in sports, could be explained by mutations uncovered by a Canada research team.

Even after the implantation of a left ventricular assist device there is no guarantee that patients will live much past the procedure. Planning for life after the implant can be as important as the time beforehand.

For many, cardiovascular disease can be seen as mostly an issue facing men. However, work has been done to raise the education of women to help ensure their health as well.

At the Heart Failure Society of America's 20th Annual Scientific Meeting, Pieter Muntendam, MD, scPharmaceuticals, discussed his work in developing a hospital strength treatment option for patients with fluid overload using the well known drug furosemide, now for subcutaneous administration.

Study results presented at the 2016 Heart Failure Society of America Scientific Meeting show that treatment with omecantiv mecarbil improved cardiac function and quality of life in patients with heart failure.

There is a known connection between atrial fibrillation and stroke risk. Finding the best way to handle this connection can determine the success of care and the quality of life for patients.

Statins should not be physicians' first option in treating all patients at high risk of cardiovascular disease, according to new European treatment guidelines.